The stock may react positively to strong revenue growth and IPO completion, but investors should monitor whether management can control cost pressures that are eroding profitability. The 2026 guidance suggests continued growth but at potentially compressed margins.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 25 $48.18entry
- T+1 · 9mo ago +1.47%α +2.02% · $48.89
- T+5 · 9mo ago −11.00%α −9.90% · $42.88
- T+20 · 8mo ago −11.44%α −6.20% · $42.67
- T+60 · 6mo ago −24.76%α −31.71% · $36.25
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Medline reported strong full-year 2025 revenue growth of 11.5% to $28.4 billion, but net income declined 3.6% to $1.2 billion due to higher costs from tariffs, headcount investments, and IPO-related expenses. Adjusted EBITDA grew 3.2% to $3.5 billion. The company completed its IPO and provided 2026 guidance for organic sales growth of 8-9% and Adjusted EBITDA of $3.5-$3.6 billion.
Key Financial Metrics
Key Facts
- Fourth quarter 2025 net sales: $7.8 billion (+14.8% YoY)
- Full year 2025 net sales: $28.4 billion (+11.5% YoY)
- Fourth quarter 2025 net income: $180 million (-37.7% YoY)
- Full year 2025 net income: $1.2 billion (-3.6% YoY)
- Full year 2025 Adjusted EBITDA: $3.5 billion (+3.2% YoY)
- Completed IPO in Q4 2025
- 2026 guidance: 8-9% organic sales growth and $3.5-$3.6 billion Adjusted EBITDA
Financial Impact
Revenue growth of 11.5% with declining profitability due to cost pressures
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| Medline Brand | $13.7K | +9.6% |
| Supply Chain Solutions | $14.7K | +13.2% |
Risk Factors
- Continued margin pressure from tariffs and operating costs
- Integration costs from acquisitions
- Execution risk on IPO-related growth initiatives
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0002046386-26-000007 |
| Document: mdln-20260225.htm | 0002046386-26-000007 |
| Document: 0002046386-26-000007-index-headers.html | 0002046386-26-000007 |
| Document: 0002046386-26-000007-index.html | 0002046386-26-000007 |
| Document: 0002046386-26-000007.txt | 0002046386-26-000007 |
Track record
30 reports on MDLN
5 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +17.95% at T+20 after the May 6, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 16, 2026today Press Release Bearish 5/10 Entry $36.40 Now $39.17 −7.61% settles Nov 23
- Nov 16, 2026today S-1 Neutral 4/10 Entry price pending
- Nov 13, 20263d ago SC 13G Neutral 3/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $42.00 Now $39.17 −6.74% settles Nov 23
- Nov 6, 202610d ago SC 13G/A Neutral 3/10 Entry $40.71 to $39.17 Now $39.17 −3.78% ▼ −3.78% −2.09% vs SPY
- Nov 4, 202612d ago 8-K Neutral 5/10 No price data
- Nov 4, 202612d ago Press Release Bullish 6/10 Entry $40.35 to $42.16 Now $39.17 −2.92% ▲ +4.49% +5.40% vs SPY
- Nov 2, 202614d ago Institutional Cluster Bearish 4/10 Entry $34.09 to $40.91 Now $39.17 −14.90% ▼ −20.01% −20.59% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 3/10 Entry $32.12 to $39.64 Now $39.17 +21.95% ▲ +23.41% +26.12% vs SPY
- Oct 21, 202626d ago 8-K Bearish 6/10 Entry $34.88 to $32.00 Now $39.17 −12.30% ▲ +8.26% +8.96% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers